HEPCVAX: Unraveling HCV pathogenicity for the preclinical development of new therapeutic strategies

• Unité de recherche: PCRD EU
• Numéro de projet: 02.0285-1
• Titre du projet anglais: HEPCVAX: Unraveling HCV pathogenicity for the preclinical development of new therapeutic strategies

Mots-clé (Italien)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Autre Numéro de projet (Anglais)

EU project number: QLK2-CT-2002-01329

Programme de recherche (Anglais)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Description succincte (Anglais)

See abstract

Résumé des résultats (Abstract) (Anglais)

The overall objectives of the HepCVax cluster is to identify viral and host mechanisms which are involved in:
i) viral replication and particle formation;
ii) pathogenicity and viral persistence and, based on the knowledge of virus properties as well as virus-host interactions and pathogenesis;
iii) to identify innovative antiviral and immuno-therapeutic strategies capable of inducing a broad and sustained HCV specific cellular-mediated immune responses. All information emerging from the understanding of the HCV genome will be integrated in the first ever-European sequence database dedicated to Hepatitis C virus. The cluster will be subdivided in three component Networks. Whereas HepCVax-PARTIC will concentration the molecular and intracellular level of the virus-host interactions through the identification of factors involved in HCV-particles formation, HepCVax. IMPA TH will focus on the interaction between HCV and different arms of the innate and adaptive immune response. HepCVax-PRECLIN will exploit the expected discoveries made by Networks 1and 2 to develop and test new immuno-therapeutic strategies in vitro and in small animal models.

Références bases de données (Anglais)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 02.0285-1